

ORIGIN

The Human Genome Project (HGP) is considered one of the greatest scientific achievements of the last century. BGI was founded in 1999 in order to participate in this significant research project. Since then, BGI has become a world-leading life science organization.



SERVICES

BGI leads innovative development in genomics and life sciences through its integrated model incorporating industry development, education and research in compliance with international bioethical protocols, and applies frontier multi-omics research findings to areas including medicine, healthcare, resource conservation, forensics and more; and provides cutting-edge proprietary life science instruments and devices, technical support and solutions to accelerate industry transfer of genomic technologies and revolutionize current healthcare system towards precision medicine and precision healthcare, using "omics" to benefit the mankind.

CORE CAPABILITIES

Scientific Research BGI·Research




25

Innovation Centers
(including 1 national and 7 provincial)



3600+

SCI Publications



1700+

Patent Applications

Sequencing Services BGI·Genomics



Reproductive Health

From the perspective of tertiary prevention and birth defect control, we conduct our research and clinical application services based on reproductive health. This covers pre-conception, newborn and child stages.



Precision Oncology

Preventing and controlling cancers through a comprehensive precision oncology system which adopts the latest technologies and products to effectively prevent, screen, diagnose and monitor tumors.



Pathogen Detection

Using technological platforms like metagenomics to test for and analyze complicated or severe infections. Depending on the different target pathogens that require detection, there are effective and complementary detection products. These are suitable for different clinical application scenarios, and provide a holistic solution for the diagnosis and treatment of clinical infectious diseases.



Genomics Big Data and Synthesis

Providing services engaging in life science research with high-quality, cutting-edge solutions, including standardized technological services, such as gene sequencing, mass spectrometry analysis, biological database management and cloud data analytics, and customized services, such as gene synthesis, Oligo synthesis and whole genome/chromosome fragment restructuring and synthesis.



Precision Medicine Solutions

Offering comprehensive precision medicine solutions and complete product lines to meet the needs of large medical institutions and support the growing market for the construction and operation of precision medicine centers.

Leading Life Science Innovation MGI



To Develop and Promote Advanced Life Science Tools for Future Healthcare

Feb. 2023, MGI launches DNBSEQ-T20x2 Ultra-high Throughput Sequencer

Sep. 2022, MGI is listed on Shanghai Stock Exchange STAR Market

Sep. 2022, MGI launches its DNBSEQ-G99 gene sequencer

Sep. 2022, MGI launches its Wireless Handheld Ultrasound H1 Series

Aug. 2022, MGI launches its DNBSEQ-E25 miniaturized gene sequencer

Jul. 2022, MGI launched its first DNBseq-D4 automated library preparation lab adopting digital microfluidic technology

Oct. 2021, launched MGISP-Smart 8 Automated Sample Preparation System and MGICLab-LT Automated Ultra-low-temperature BioBank

Apr. 2021, launched Robotic Ultrasound Vehicle

Jan. 2021, launched MGISP-NE384, high-throughput automated nucleic acid extractor

Oct. 2020, launched DNBSEQ-T10x4RS genetic sequencing system


Oct. 2019, launched DNBSEQ E, DNBelab D and DNBelab C series

Oct. 2018, launched ultra-high-throughput sequencer DNBSEQ-T7, MGISP-960 high-throughput automated sample preparation system

Oct. 2017, launched high-throughput sequencers DNBSEQ-G400 and DNBSEQ-G50, robotic ultrasound system MGIUS-R3

Mar. 2013, acquisition of Complete Genomics, a US biotech company

Storage and Reading of Genetic Resources



Reading – Digitalization Platform

A leading "reading" platform producing petabytes of data annually

Storage – Biorepository

An automated, low-cost and high-throughput biorepository

Storage – Biological Resource Center of Plants, Animals and Micro-organisms

Building a digitalized biodiversity conservation base and biological resource center

Storage – Bio-informatics Data Center

A secured database and highly efficient bio-informatics analysis platform

China National GeneBank DataBase (CNCBdb)

A comprehensive database for biological data sharing and applications

QUICK FACTS



1999

BGI was founded in 1999.



10000+

BGI has more than 10000 employees worldwide.



100+

Services and solutions are available in 100+ countries and regions.



Shenzhen

Headquartered in Shenzhen.



31

Services and solutions are available in 31 provinces, autonomous regions and municipalities in Mainland China.





430+

430+ scientific papers published in the world's leading journals such as *Nature* series, *Science* series, *Cell* series, and *New England Journal of Medicine*.

GLOBAL PRESENCE

BGI is headquartered in Shenzhen, with services and solutions available in more than 100 countries and regions around the world.



ORGANIZATIONS

BGI·Research



BGI·Research is one of the top ten basic research institutions in Shenzhen. After years of dedication in genomic research, BGI·Research has become a world-leading research center. Focusing on developing gene reading, writing and storage technologies, and leading international big data and disease prevention mega-science programs, BGI·Research aims to establish a comprehensive scientific research system covering bioinformatics, human genomics, agricultural genomics, microbiology, and marine biology.



GigaScience

Launched in July 2012, *GigaScience* aims to revolutionize publishing by promoting reproducibility of scientific research analyses, data dissemination, organization, understanding, and use.



BGI·College


Specialized in innovative higher education and training at international standard to foster future talents in life sciences for advancing scientific research and development.

China National GeneBank (Operated by BGI·Research)



China National GeneBank (CNCB) is one of the key science infrastructures in Shenzhen, approved and funded by the Chinese government. CNCB is committed to supporting public welfare, life science research, innovation and industry development, through effective bioresource conservation, digitalization and utilization. China National GeneBank (CNCB) is owned by the government and operated independently by BGI·Research under the guidance and supervision of State High-Tech Industrial Innovation Center, Shenzhen (HIIC).

BGI·MED



Engaged in the clinical transformation and application of gene science and technology achievements, enabling patients to receive accurate diagnosis and treatment, promoting the transformation from traditional medicine to precision medicine.

Mammoth Foundation



China's first public welfare foundation that works for public benefit based on gene technology was co-initiated by BGI, Vanke Foundation, Green Pine Capital and Galaxy Holding Group. We take aim at "working together on charity and making all benefit from gene technology". We uphold the principle of promoting and developing gene technology that is people-oriented, equal, all-inclusive, convenient and accessible. We mainly work on medical subsidy and assistance, popular science & education, and crossover communication among others.

BGI·Genomics (Shenzhen Stock Exchange: 300676)



A world leader in scientific and precision medicine services that:

- provides leading research and precision medicine solutions to science institutes, enterprises, medical facilities and healthcare organizations
- works to advance technological innovation, reduce birth defects, fight tumors and protect against serious illness
- promotes precision medicine to cure infections

MGI (Shenzhen Stock Exchange: 688114)



MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time, panoramic, and full-life-cycle equipment and systems for precision medicine, precision agriculture, precision healthcare and other relevant industries. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.

FGL



FGL is committed to providing world-leading high-accuracy forensic DNA testing to benefit the society. FGL innovates forensic application through integrating industry, education, and research. It has one of the first third-party centers approved by Ministry of Justice of China.

BGI·Bioverse

BGI Bioverse—"Harmony of nature and human, coexistence of all creatures." It is committed to develop new breeding technologies and cultivate new varieties through whole-genome design, gene editing and synthetic biology, which relies on BGI's genome big data platform. It applies desert soilization technologies to desert transformation, contributes to the coordinated development of green ecology, climate, soil environment and biology, which are the basic elements of agricultural practices.

BGI·Health

BGI Health aims to provide precision health services and solutions by analyzing multi-omic data for BGI employees and their families, including precision prevention, intervention and improvement. It strives to provide full-life-cycle precision health services for more people in future.

To learn more about us, please visit



Facebook



Twitter



Website

E-mail: info@genomics.cn / media@genomics.cn

Copyright ©2023 BGI. All Rights Reserved. (2023.3)